Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Rijkevorsel – page 41

1 144 clinical trials in Rijkevorsel, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Rijkevorsel at a glance
1 144
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 144 trials in Rijkevorsel

Open in trial search

Non-small cell lung cancer+1

Not yet recruiting

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Chronic lymphocytic leukaemia+2

Not yet recruiting

Study of Ibrutinib Plus Ritonavir in Adults with Chronic Lymphocytic Leukemia, Lymphoplasmacytic Lymphoma, and Mantle Cell Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Adenocarcinoma pancreas

Not yet recruiting

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Crohn's disease

Not yet recruiting

Evaluation of Upadacitinib for Reducing Ileal Strictures in Patients with Crohn’s Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:UZ Leuven

Endometrial cancer

Not yet recruiting

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:GSK5733584
  • Sponsor:Glaxosmithkline Research & Development Limited

Safety and Immune Response of GBS‑NN/NN2 Vaccine in Pregnant Women and Their Infants to Prevent Group B Streptococcus Infection

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:GBS-NN
  • Sponsor:Minervax ApS

Randomized Phase 3 Study of Deupirfenidone (LYT‑100) versus Pirfenidone in Adults with Idiopathic Pulmonary Fibrosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Deupirfenidone
  • Sponsor:Celea Therapeutics Inc.

Epcoritamab plus rituximab versus rituximab alone in elderly, frail or unfit patients with newly diagnosed diffuse large B‑cell lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Epcoritamab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Gastrooesophageal cancer

Not yet recruiting

Perioperative Zanidatamab and Tislelizumab with Chemotherapy for Patients with HER2‑Positive Locally Advanced Operable Gastroesophageal Adenocarcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tislelizumab
  • Sponsor:UZ Leuven

Neoplasm

Not yet recruiting

Long‑term Safety of Adagrasib with Drug Combination in Adults with Solid Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of dupilumab added to standard care in adults hospitalized for COPD exacerbation to reduce readmissions, emergency visits, and death

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.